#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4306	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2498	321.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1520	1520	C	512	C	314	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7738	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3581	404.1	0	.	n	.	0	T695C	SNP	695	695	T	1048	1048	C	545	C,A	343,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7738	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3581	404.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1690	1690	A	351	A	238	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7738	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3581	404.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2324	2324	C	485	C	319	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7738	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3581	404.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2950	2950	T	397	T	253	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7738	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3581	404.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2398	2398	A	503	A	323	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	264	folP	852	852	100.0	folP.l15.c4.ctg.1	1666	30.4	1	SNP	p	R228S	1	.	.	682	684	AGC	1133	1135	AGC	34;36;34	A,G;G;C	19,1;22;21	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	806	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3541	41.2	1	SNP	p	S91F	0	.	.	271	273	TCC	662	664	TCC	55;55;55	T;C;C	32;32;31	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	806	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3541	41.2	1	SNP	p	D95G	0	.	.	283	285	GAC	674	676	GAC	58;59;59	G;A;C	33;32;33	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	806	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3541	41.2	1	SNP	p	D95N	0	.	.	283	285	GAC	674	676	GAC	58;59;59	G;A;C	33;32;33	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	216	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1255	32.7	0	.	p	.	0	A39T	NONSYN	115	117	GCC	422	424	ACC	58;58;58	A;C;C	35;35;36	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	216	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1255	32.7	0	.	p	.	0	R44H	NONSYN	130	132	CGC	437	439	CAC	63;63;65	C;A;C	38;38;38	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	216	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1255	32.7	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	620	622	CAC	37;37;36	C;A;C	23;23;24	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	216	mtrR	633	633	99.21	mtrR.l6.c17.ctg.1	1255	32.7	1	SNP	p	G45D	0	.	.	133	135	GGC	440	442	GGC	65;67;67	G;G;C	39;41;40	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	156	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	797	37.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	790	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3034	48.2	1	SNP	p	D86N	0	.	.	256	258	GAC	686	688	GAC	62;62;62	G;A;C	36;34;38	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	790	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3034	48.2	1	SNP	p	S87R	0	.	.	259	261	AGT	689	691	AGT	62;63;64	A;G;T	38;41;39	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	790	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3034	48.2	1	SNP	p	S87W	0	.	.	259	261	AGT	689	691	AGT	62;63;64	A;G;T	38;41;39	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	790	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3034	48.2	1	SNP	p	S87I	0	.	.	259	261	AGT	689	691	AGT	62;63;64	A;G;T	38;41;39	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	790	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3034	48.2	1	SNP	p	S88P	0	.	.	262	264	TCC	692	694	TCC	65;65;62	T;C;C	38;40;39	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	656	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3135	40.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1884	1886	GGC	51;51;51	G;G;C	33;34;32	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2111	62.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1133	1135	GCA	92;95;98	G;C,G;A	56;60,1;60	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2111	62.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1136	1138	ATC	100;100;100	A;T;C	61;62;63	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2111	62.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1148	1150	GTG	97;97;96	G,C;T;G	59,1;54;60	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2111	62.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1148	1150	GTG	97;97;96	G,C;T;G	59,1;54;60	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2111	62.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1652	1654	ACC	40;42;41	A;C;C	24;31;30	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2111	62.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1706	1708	GCG	30;30;30	G;C;G	24;23;24	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2111	62.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1706	1708	GCG	30;30;30	G;C;G	24;23;24	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2111	62.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1829	1831	GGC	25;25;25	G;G;C	17;18;15	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2111	62.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1838	1840	GGC	24;20;18	G;G;C	16;13;11	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	702	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2111	62.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1856	1858	CCG	21;21;20	C,G;C;G	13,1;12;12	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1260	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	2844	77.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	348	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2235	28.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	635	635	C	19	C	11	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	380	porB1b	1035	1035	95.92	porB1b.l15.c17.ctg.1	1665	41.7	0	.	p	.	0	E48G	NONSYN	142	144	GAA	546	548	GGA	61;61;60	G;G;A	37;38;38	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	380	porB1b	1035	1035	95.92	porB1b.l15.c17.ctg.1	1665	41.7	0	.	p	.	0	F135L	NONSYN	403	405	TTT	807	809	CTT	36;36;36	C;T;T	26;25;26	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	380	porB1b	1035	1035	95.92	porB1b.l15.c17.ctg.1	1665	41.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	831	833	GGA	41;42;42	G;G;A	28;28;25	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	380	porB1b	1035	1035	95.92	porB1b.l15.c17.ctg.1	1665	41.7	0	.	p	.	0	G189S	NONSYN	565	567	GGC	969	971	AGC	50;50;50	A;G;C	33;31;33	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	380	porB1b	1035	1035	95.92	porB1b.l15.c17.ctg.1	1665	41.7	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1035	1035	T	35	T	24	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	380	porB1b	1035	1035	95.92	porB1b.l15.c17.ctg.1	1665	41.7	1	SNP	p	G120K	0	.	.	358	360	GGT	762	764	GGT	32;33;31	G;G;T,G	23;22;18,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	380	porB1b	1035	1035	95.92	porB1b.l15.c17.ctg.1	1665	41.7	1	SNP	p	A121N	0	.	.	361	363	GCC	765	767	GCC	34;34;34	G;C;C	25;22;26	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	380	porB1b	1035	1035	95.92	porB1b.l15.c17.ctg.1	1665	41.7	1	SNP	p	A121D	0	.	.	361	363	GCC	765	767	GCC	34;34;34	G;C;C	25;22;26	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2106	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5157	76.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2095	2097	AAT	95;94;94	A;A;T	59;61;59	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	238	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	976	49.5	1	SNP	p	V57M	1	.	.	169	171	ATG	535	537	ATG	77;75;77	A;T;G	58;57;55	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
